{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:27:02Z","timestamp":1787023622923,"version":"build-2736575974"},"reference-count":75,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,2,5]]},"DOI":"10.18632\/oncotarget.28547","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:26:43Z","timestamp":1707132403000},"page":"65-75","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma"],"prefix":"10.18632","volume":"15","author":[{"given":"Ashley","family":"Del Dosso","sequence":"first","affiliation":[{"name":"ONCOtherapeutics, West Hollywood, CA 90069, USA"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tadevosyan","sequence":"additional","affiliation":[{"name":"Berenson Cancer Center, West Hollywood, CA 90069, USA"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[{"name":"ONCOtherapeutics, West Hollywood, CA 90069, USA"},{"name":"Berenson Cancer Center, West Hollywood, CA 90069, USA"},{"name":"Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, Staging, and Management of Multiple Myeloma","volume":"9","author":"Ajebo","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"11","author":"Pulte","year":"2008","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"3","author":"Richardson","year":"2017","journal-title":"Leukemia"},{"key":"4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11523-023-00990-6","article-title":"Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients","volume":"1","author":"Berenson","year":"2023","journal-title":"Target Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple Myeloma: Available Therapies and Causes of Drug Resistance","volume":"1","author":"Vasconcelos","year":"2020","journal-title":"Cancers (Basel)"},{"key":"6","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche","volume":"1","author":"Racanelli","year":"2022","journal-title":"Front Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"11","author":"Tedder","year":"2008","journal-title":"Blood"},{"key":"8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"2","author":"Anderson","year":"2009","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/cancers13112542","article-title":"Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression","volume":"1","author":"Garayoa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","article-title":"Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming","volume":"2","author":"Wang","year":"2022","journal-title":"Mol Cancer"},{"key":"11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"12","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"2","author":"Babon","year":"2018","journal-title":"Protein Sci"},{"key":"13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2050-7771-1-5","article-title":"Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application","volume":"1","author":"Liu","year":"2013","journal-title":"Biomark Res"},{"key":"14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"11","author":"Harrison","year":"2004","journal-title":"J Cell Sci"},{"key":"15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","article-title":"Ruxolitinib: a review of its use in patients with myelofibrosis","volume":"7","author":"Plosker","year":"2015","journal-title":"Drugs"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8081.1","article-title":"Recent advances in understanding myelofibrosis and essential thrombocythemia","volume":"5","author":"Plo","year":"2016","journal-title":"F1000Res"},{"key":"17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"3","author":"Barbui","year":"2016","journal-title":"Leukemia"},{"key":"18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.18593","article-title":"Ruxolitinib and methylprednisolone for treatment of patients with relapsed\/refractory multiple myeloma","volume":"20","author":"Regidor","year":"2023","journal-title":"Br J Haematol"},{"key":"19","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-19-1899","article-title":"A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"2","author":"Moss","year":"2020","journal-title":"Clin Cancer Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hon.3066","article-title":"A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed\/refractory multiple myeloma patients","volume":"4","author":"Moss","year":"2022","journal-title":"Hematol Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00277-019-03595-0","article-title":"The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combinationand","volume":"9","author":"Berenson","year":"2019","journal-title":"Ann Hematol"},{"key":"22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/bjh.16158","article-title":"JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression","volume":"18","author":"Tang","year":"2020","journal-title":"Br J Haematol"},{"key":"23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bjh.17282","article-title":"Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma","volume":"19","author":"Huang","year":"2021","journal-title":"Br J Haematol"},{"key":"24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/hon.3071","article-title":"The JAK1\/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma","volume":"4","author":"Berenson","year":"2023","journal-title":"Hematol Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"4","author":"Schumacher","year":"2018","journal-title":"Immunity"},{"key":"26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"1","author":"Pauken","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"1","author":"Johnson","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/cancers12040924","article-title":"PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma","volume":"1","author":"Inokuchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"2","author":"Anderson","year":"2015","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"1","author":"Xiong","year":"2019","journal-title":"Mol Cancer"},{"key":"31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","article-title":"The intracellular signalosome of PD-L1 in cancer cells","volume":"3","author":"Kochan","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"37","author":"Neiman","year":"2018","journal-title":"N Engl J Med"},{"key":"33","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"18","author":"Islam","year":"2023","journal-title":"Cell"},{"key":"34","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"36","author":"Antonia","year":"2012","journal-title":"N Engl J Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma","volume":"1","author":"Thair","year":"2019","journal-title":"Front Immunol"},{"key":"36","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"12","author":"Menzies","year":"2017","journal-title":"Cancer"},{"key":"37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies","author":"Armand","year":"2016","journal-title":"Blood"},{"key":"38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","volume":"6","author":"Gordon","year":"2014","journal-title":"F1000Prime Rep"},{"key":"39","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3109\/10428194.2013.778409","article-title":"Macrophages in multiple myeloma: emerging concepts and therapeutic implications","volume":"5","author":"Hematti","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"15","author":"Hematti","year":"2012","journal-title":"Br J Haematol"},{"key":"41","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1182\/bloodadvances.2021005327","article-title":"Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNF\u03b1","volume":"5","author":"Fooksman","year":"2021","journal-title":"Blood Adv"},{"key":"42","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"11","author":"Yi","year":"2009","journal-title":"Blood"},{"key":"43","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1172\/JCI85782","article-title":"Alternatively activated macrophages determine repair of the infarcted adult murine heart","volume":"12","author":"Suzuki","year":"2016","journal-title":"J Clin Invest"},{"key":"44","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1073\/pnas.94.4.1074","article-title":"Nuclear integration of JAK\/STAT and Ras\/AP-1 signaling by CBP and p300","volume":"9","author":"Glass","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"45","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond","volume":"1","author":"Ullah","year":"2019","journal-title":"J Bone Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression","volume":"1","author":"Mart\u00ednez-L\u00f3pez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"1","author":"Kneissel","year":"2013","journal-title":"Nat Med"},{"key":"48","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/bjh.14801","article-title":"MUC1-C is a target in lenalidomide resistant multiple myeloma","volume":"17","author":"Kufe","year":"2017","journal-title":"Br J Haematol"},{"key":"49","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1182\/blood-2006-08-041202","article-title":"Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis","volume":"10","author":"Nakamura","year":"2007","journal-title":"Blood"},{"key":"50","doi-asserted-by":"publisher","first-page":"42553","DOI":"10.18632\/oncotarget.9924","article-title":"Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas","volume":"7","author":"Tasaki","year":"2016","journal-title":"Oncotarget"},{"key":"51","doi-asserted-by":"publisher","first-page":"112575","DOI":"10.1016\/j.yexcr.2021.112575","article-title":"PD-L1 induces macrophage polarization toward the M2 phenotype via Erk\/Akt\/mTOR","volume":"40","author":"Jiang","year":"2021","journal-title":"Exp Cell Res"},{"key":"52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2022.07.004","article-title":"Correlation between PD-1\/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy","volume":"6","author":"Cui","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Verma","year":"2009","journal-title":"J Hematol Oncol"},{"key":"54","first-page":"9932","article-title":"The role of Wnt\/\u03b2-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review)","volume":"1","author":"Yang","year":"2021","journal-title":"Am J Transl Res"},{"key":"55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11523-021-00821-6","article-title":"Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed\/Refractory Multiple Myeloma Starting New Therapy","volume":"1","author":"Rahbari","year":"2021","journal-title":"Target Oncol"},{"key":"56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bjh.16752","article-title":"Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment","volume":"19","author":"Rahbari","year":"2021","journal-title":"Br J Haematol"},{"key":"57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.13666","article-title":"Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma","volume":"10","author":"Chen","year":"2021","journal-title":"Eur J Haematol"},{"key":"58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0960-0760(02)00223-6","article-title":"Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones","volume":"8","author":"Shatskaya","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"59","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"1","author":"Grandis","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"60","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1182\/blood-2023-180287","article-title":"A phase 1 trial evaluating the addition of lenalidomide to relapsed\/refractory multiple myeloma patients progressing on ruxolitinib and methylprednisolone","volume":"14","author":"Eades","year":"2023","journal-title":"Blood"},{"key":"61","doi-asserted-by":"publisher","first-page":"e22585","DOI":"10.7759\/cureus.22585","article-title":"Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management","volume":"1","author":"Sange","year":"2022","journal-title":"Cureus"},{"key":"62","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.clml.2022.01.012","article-title":"A Phase 1\/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies","volume":"2","author":"Savona","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"63","first-page":"500","article-title":"The role of JAK inhibitors in multiple myeloma","volume":"1","author":"Berenson","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12185-022-03335-7","article-title":"Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives","volume":"11","author":"Vannucchi","year":"2022","journal-title":"Int J Hematol"},{"key":"65","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications","volume":"13","author":"Anderson","year":"2020","journal-title":"Blood"},{"key":"66","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"37","author":"Khan","year":"2015","journal-title":"N Engl J Med"},{"key":"67","doi-asserted-by":"publisher","first-page":"15330338221106563","DOI":"10.1177\/15330338221106563","article-title":"Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab","volume":"2","author":"Shen","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"68","doi-asserted-by":"publisher","first-page":"100214","DOI":"10.1016\/j.clinpr.2022.100214","article-title":"Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma","volume":"1","author":"Berenson","year":"2023","journal-title":"Clin Infect Pract"},{"key":"69","doi-asserted-by":"publisher","first-page":"e220446","DOI":"10.1001\/jamaoncol.2022.0446","article-title":"Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients","volume":"8","author":"Ribi","year":"2022","journal-title":"JAMA Oncol"},{"key":"70","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"3","author":"Swift","year":"2021","journal-title":"Leukemia"},{"key":"71","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/S2665-9913(22)00044-3","article-title":"Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Shu","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"72","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"3","author":"Kiladjian","year":"2021","journal-title":"Leukemia"},{"key":"73","doi-asserted-by":"publisher","first-page":"108517","DOI":"10.1016\/j.clim.2020.108517","article-title":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","volume":"21","author":"Langmuir","year":"2020","journal-title":"Clin Immunol"},{"key":"74","doi-asserted-by":"publisher","first-page":"e003766","DOI":"10.1136\/jitc-2021-003766","article-title":"JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibodyefficacy","volume":"1","author":"Larivi\u00e8re","year":"2022","journal-title":"J Immunother Cancer"},{"key":"75","doi-asserted-by":"publisher","first-page":"2083479","DOI":"10.1080\/2162402X.2022.2083479","article-title":"Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors","volume":"1","author":"Klein","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:26:50Z","timestamp":1707132410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2,5]]}},"alternative-id":["28547"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28547","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]}}}